Interstitial glucose monitoring, type 1 diabetes and COVID-19 vaccine: the patient-reported outcomes and vaccine-associated changes in glucose and side effects (PRO-VACS).

On the other hand, since diabetes is associated with a worse outcome of COVID-19 [[3]], vaccination is particularly recommended in patients with T1D. Keywords: COVID-19; Diabetes; Vaccine EN COVID-19 Diabetes Vaccine 435 438 4 02/23/22 20220301 NES 220301 Introduction In the available phase 3 trial, mRNA-1273 (Moderna) COVID-19 vaccine showed a high efficacy together with a good tolerability [[1]]. Since vaccination does not imply any relevant negative consequence on glycemic control, concerns about the effects of vaccine on glycemia should not contribute to vaccine hesitancy in people with T1D diabetes, and this is especially important for advocating clearly about the need for vaccinate all these subjects against COVID-19. [Extracted from the article]